A trial to investigate RedeeFlu in healthy volunteers

Trial Profile

A trial to investigate RedeeFlu in healthy volunteers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 May 2018

At a glance

  • Drugs H3N2 M2SR influenza vaccine-FluGen (Primary)
  • Indications Influenza A virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 May 2018 Planned number of patients changed from 100 to 96, as reported in a FluGen media release.
    • 16 May 2018 According to a FluGen media release, the first subject has been dosed in this trial. The study is being conducted by SGS. The study is supported by a grant from the Department of Defense. The U.S. Army Medical Research Acquisition Activity is the awarding and administering acquisition office and this work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program under Award No. W81XWH-17-1-0430.
    • 16 May 2018 Status changed from planning to recruiting, as reported in a FluGen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top